Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice.
about
Management of osteoporosisThe Metabolic Implications of Glucocorticoids in a High-Fat Diet Setting and the Counter-Effects of ExerciseDisabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivoOsteoporosis prophylaxis in patients receiving chronic glucocorticoid therapyThe osteogenesis-promoting effects of alpha-lipoic acid against glucocorticoid-induced osteoporosis through the NOX4, NF-kappaB, JNK and PI3K/AKT pathways.Patterns of bone mineral density testing: current guidelines, testing rates, and interventionsAdvances in glucocorticoid-induced osteoporosisSteroids cause osteoporosis.Access to bone densitometry increases general practitioners' prescribing for osteoporosis in steroid treated patients.Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial.Osteoprotegerin Polymorphisms in a Mexican Population with Rheumatoid Arthritis and Generalized Osteoporosis: A Preliminary ReportEffects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis.Tanshinone IIA blocks dexamethasone-induced apoptosis in osteoblasts through inhibiting Nox4-derived ROS production.Recovery of Adrenal Function in Patients with Glucocorticoids Induced Secondary Adrenal InsufficiencyOsteoporosis prevention among chronic glucocorticoid users: results from a public health insurance database.Management of glucocorticoid-induced osteoporosis.Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions.Longitudinal practice patterns of prophylaxis of glucocorticoid-induced osteoporosis in patients with polymyalgia rheumatica.Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in FranceBurden of systemic glucocorticoid-related complications in severe asthma.In vitro and in vivo inhibition of glucocorticoid-induced osteoporosis by the hexane extract of Poncirus trifoliata.Novel fat depot-specific mechanisms underlie resistance to visceral obesity and inflammation in 11 β-hydroxysteroid dehydrogenase type 1-deficient mice.Prevalence of oral glucocorticoid usage in the United States: a general population perspective.Glucocorticoids, Inflammation and Bone.Infliximab for rheumatoid arthritis.Negative impact of high cumulative glucocorticoid dose on bone metabolism of patients with myasthenia gravis.BMD values and GSTM3 gene polymorphisms in combination with GSTT1/GSTM1 genes: a genetic association study in Slovenian elderly.
P2860
Q24795473-1B56C9DC-C0BE-4EB6-8A3A-182E9D31E4E0Q28076700-3659BB76-78FA-4E91-AC94-DA4842D7C4D4Q28191731-DE9ACD03-1CC5-43FC-B257-DCCF0B9B7FCDQ33619648-D413D1F4-8755-4106-B7C5-2FE21D08F5B2Q33794181-4B862D41-DBEB-449E-90D5-77A3DFF3FFB4Q34733243-F48C2774-3419-4B2D-8D06-BBB08B89494DQ34975913-AFBA19C3-122F-4ED0-86B8-A8C2FEAA4E7EQ35550904-01B124BF-07E8-460D-B259-2407A8A00B7EQ35553822-6D4A6E06-4E22-4BEC-B319-B52646A94239Q35554275-6BF469D7-2F3C-4ACC-803E-CB33484AF0E1Q35612713-888CEB16-1171-45A8-9214-0D45BA3BD3A2Q35868276-2DA2FB75-B363-4CE8-B303-E9A65AA160A3Q36375631-9D2399C6-B970-4658-9584-29561B6089DBQ36717014-3D7AC339-66B8-461A-8D54-5234F152BDA6Q37100828-421EB70B-5087-42D9-8287-7A8438B6FA16Q38033444-34644E48-4930-488D-B235-C438267DE86EQ38073889-7C44C797-92D9-44EF-A8F4-B1B81499F974Q38204240-15D0531E-6FA8-4AC8-84AE-880E630FF7F8Q38650895-44DD19D6-A492-4E17-8C25-5BE02D428A16Q39391610-4EAC05B5-1EC9-4FD2-874F-46D12D3F8221Q39608918-B988184C-D64E-48AC-A0FC-43222B3E4B87Q42703602-033E8BA0-D889-46C5-9AF8-ABA4CDCA753DQ47373968-AEF0C732-508C-41D7-9F08-1EDD678B48F2Q50128187-E6F7A5C5-8968-4004-8980-02CE5A68912BQ52856626-8B50A8BA-2945-49D5-8511-63DDDC13EA2BQ53496648-B33D4DB9-480C-48F8-A9D4-15E73958A3C6Q54324592-7D18A9E9-A1BF-403F-9251-9227142B4017
P2860
Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Prevalence of long term steroi ...... is in daily clinical practice.
@ast
Prevalence of long term steroi ...... is in daily clinical practice.
@en
type
label
Prevalence of long term steroi ...... is in daily clinical practice.
@ast
Prevalence of long term steroi ...... is in daily clinical practice.
@en
prefLabel
Prevalence of long term steroi ...... is in daily clinical practice.
@ast
Prevalence of long term steroi ...... is in daily clinical practice.
@en
P2093
P2860
P356
P1476
Prevalence of long term steroi ...... is in daily clinical practice.
@en
P2093
Gudbjornsson B
Gudjonsson FV
Juliusson UI
P2860
P356
10.1136/ARD.61.1.32
P407
P577
2002-01-01T00:00:00Z